EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer

Novartis (NVS) announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population.The EC has approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence.Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of ...